Eastmoney has recently unveiled the top 500 Chinese listed companies in 2017, wherein, there are 42 pharmaceutical enterprises, and Hengrui Medicine, Kangmei Pharmaceutical, Fosun Pharmaceutical, and Yunnan Baiyao are the four with market value exceeding RMB 100 billion. From the data released, the market value of the pharmaceutical enterprises in the list has experienced significant growth: Hengrui Medicine rose to the top among pharmaceutical enterprises with its market value nearly doubled and approaching nearly RMB 200 billion, and pharmaceutical enterprises like BeiGene even had more than 300% growth, like taking a rocket.

|
Ranking |
Pharmaceutical enterprise name |
2017 market value (RMB 100 million) |
2016 market value (RMB 100 million) |
Headquarters |
|
1 |
Hengrui Medicine |
1,943 |
1,068 |
Jiangsu |
|
2 |
Kangmei Pharmaceutical |
1,112 |
883 |
Guangdong |
|
3 |
Fosun Pharmaceutical |
1,110 |
559 |
Shanghai |
|
4 |
Yunnan Baiyao |
1,060 |
793 |
Yunnan |
|
5 |
Shanghai RAAS |
987 |
1,147 |
Shanghai |
|
6 |
Sino Biopharmaceutical |
859 |
362 |
Hong Kong, S.A.R., China, Beijing |
|
7 |
BGI |
832 |
2017 newly listed |
Guangdong (Shenzhen) |
|
8 |
Sinopharm Group |
782 |
791 |
Zhejiang (Hangzhou) |
|
9 |
Shanghai Pharma |
650 |
526 |
Shanghai |
|
10 |
Meinian Onehealth |
569 |
319 |
Shanghai |










(All Rights Reserved)